Elle Investments Research Report: ACRX

 

Company: AcelRx Pharmaceuticals, Inc.

Symbol: ACRX

Analysis Date: 5/26/20

Analysis Price: $1.52

Price Target (PT): $5.80

Upside: 282%

Dividend: NA

Recommendation: Buy

 

ACRX: 5-Year Chart

Source: Seeking Alpha

INVESTMENT THESIS:

ACRX’s lead product Dsuvia, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain, continues to gain hospital formulary wins, and management has finally begun to disclose dollar amounts for future orders from the Department of Defense (DOD). Another round of dilution remains a real possibility, as sales have ramped up much slower than investors were hoping for. But we remain bullish on Dsuvia becoming a successful niche product that can eliminate the need for IV morphine in certain instances. We think ACRX is a Buy.

LIQUIDITY POSITION: Fair

As of 1Q20, ACRD had cash and cash equivalents of $53M, with a quarterly burn rate of about $14M. The cash burn rate should improve towards the second half of 2020, as the initial orders from the Army begin to kick in. Still, it would not surprise us if another stock offering is needed.

COMMERCIAL PROSPECTS: Very Good

Previous peak net sales estimates for Dsuvia from both management and analysts have been at $1B+. At the moment sales are essentially zero, but management has made it clear that getting hospitals to place Dsuvia on their formulary can take up to a year. Once a drug has been added to the formulary, orders can then begin to be placed. Also, discussions with the DOD took some time, but it was recently disclosed that just the initial stocking orders for the Army will be about $30M over the next three years. The ramp up will be slow, but we remain bullish on the commercial prospects.

CONCLUSION:

ACRX has finally gotten Dsuvia approved and is working on building the sales channel at both hospitals and the DOD. It looks like it will be a slow ramp up, so another round of dilution is possible. But we like the chances of commercial success for Dsuvia, and think ACRX is a Buy.

Note: Additional commentary from Elle Investments can be found at http://elle-investments.com. We welcome your feedback. Additionally, we are thinking of launching a subscription service that would offer early access to our research, along with some other features that investors might find useful (i.e. general portfolio management strategies, live blog updates highlighting our reaction to breaking news, etc.). If you would be interested in subscribing to such a service, please let us know.

Published By: Elle Investments Research Team

Phone: (914) 715-8066

Email: info@elle-investments.com

Disclaimer: The Elle Investments portfolio is managed utilizing a “quantamental” approach where each position, while based on Fundamental Analysis, is sized as part of a larger quantitative portfolio. The commentary presented here is for research purposes only and is not to be taken as investment advice. Readers are expected to perform their own due diligence and/or hire an investment professional prior to entering/exiting positions. Published research ideas are related to the specific market price and publicly available information at the time of research submission/publication. Elle Investments will enter/exit positions without notice.